Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;32(7):844-851.
doi: 10.1016/j.hlc.2023.05.016. Epub 2023 Jun 22.

Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics

Affiliations
Review

Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics

Yen-Nien Lin et al. Heart Lung Circ. 2023 Jul.

Abstract

Ventricular arrhythmias (VAs) represent a major cause of sudden cardiac death and afflict patients with heart failure from both ischaemic and non-ischaemic origins, and inherited cardiomyopathies. Current VA management, including anti-arrhythmic medications, autonomic modulation, implantable cardioverter-defibrillator implantation, and catheter ablation, remains suboptimal. Catheter ablation may even cause significant cardiomyocyte loss. Cell-based therapies and exosome treatment have been proposed as promising strategies to lessen cardiomyocyte death, modulate immune reaction, and reduce myocardial scarring, and, therefore, are potentially beneficial in treating VAs. In this review, we summarise the current cornerstones of VA management. We also discuss recent advances and ongoing evidence regarding cell-based and exosome therapy, with special attention to VA treatment.

Keywords: Cardiosphere-derived cells; Catheter ablation; Exosomes; Extracellular Vesicles; Stem cells; Ventricular arrhythmias.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the effects of catheter ablation and exosome-based therapies on the ventricular arrhythmogenic substrate.
Figure 2
Figure 2
Effects of exosome-based therapy on arrhythmogenic cardiomyopathy. (A) Quantification of ventricular arrhythmias over twenty-four hours. (B) Incidence of ventricular tachycardia and fibrillation induced by programmed electrical stimulation. (C) Representative gross pathology (top) and Masson’s trichrome-stained micrographs. (D) Representative images from immunohistochemical staining for nuclear factor-kB and α-sarcomeric actinin (ASA) and quantification of nuclei positive for nuclear factor-kB. Reproduced with permission from (Lin et al., 2021) [59]. Copyright © 2023, Oxford University Press. Abbreviations: VAs, ventricular arrhythmias; VT, ; VF, ; Dsg2, ; WT, ; Veh, ; EV, ; DSG2; MT, ; RV, LV,
Figure 3
Figure 3
Effects of exosome-based therapy on ischemia cardiomyopathy. (A) Representative traces of programmed electrical stimulation in a porcine model of myocardial infarction. (B) Representative isochronal maps of areas of late activation in myocardial infarction. (C) Picrosirius red-stained sections of the infarct zone of infarcted pigs. Reproduced with permission from (Dawkins et al., 2022) [60]. Copyright © 2023, Oxford University Press. Abbreviations: CDCEXO,.

Similar articles

Cited by

References

    1. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm. 2020;17:e2–154. - PMC - PubMed
    1. Amoni M, Dries E, Ingelaere S, Vermoortele D, Roderick HL, Claus P, et al. Ventricular arrhythmias in ischemic cardiomyopathy—new avenues for mechanism-guided treatment. Cells. 2021;10:2629. - PMC - PubMed
    1. Gräni C, Benz DC, Gupta S, Windecker S, Kwong RY. Sudden cardiac death in ischemic heart disease: from imaging arrhythmogenic substrate to guiding therapies. JACC: Cardiovasc Imaging. 2020;13:2223–38. - PubMed
    1. Kirubakaran S, Bisceglia C, Silberbauer J, Oloriz T, Santagostino G, Yamase M, et al. Characterization of the arrhythmogenic substrate in patients with arrhythmogenic right ventricular cardiomyopathy undergoing ventricular tachycardia ablation. EP Europace. 2017;19:1049–62. - PubMed
    1. Pappone C, Ciconte G, Manguso F, Vicedomini G, Mecarocci V, Conti M, et al. Assessing the malignant ventricular arrhythmic substrate in patients with Brugada syndrome. J Am Coll Cardiol. 2018;71:1631–46. - PubMed

MeSH terms

Substances